Clinical trials have been completed in Europe, and Akkolens is anticipating a CE mark. Expanding PC-IOL Options Expected to Fuel Demand Among Patients.
Susan Cotter, Dashaini Retnasothie, Silvia Han, Angela Chen, Kristine Huang, and Reena Patel Why It’s Important: Myopia or “nearsightedness” occurs when the eye grows too long.
(Toric designs correct astigmatism.) THE FAILED Synchrony (developed by Visiogen) was a mechanical accommodating IOL with two lenses that moved closer or farther apart to change focus.
When Abbott Medical Optics (AMO) acquired Visogen for 0 million in 2009, Synchrony had just received CE marking in Europe.
In April 2011, Alcon was acquired by Swiss-based Novartis.
The company declined to invest in a subsequent round, and Elenza has claimed Novartis is attempting to “exploit the technologies invented by Elenza and to capture for itself 100 percent of the anticipated revenues from the commercialization of Elenza’s technologies.” The matter is in litigation.
The FDA approved the original version of Crystalens in 2003, at which time it was developed and marketed by a startup company called eyeonics.
As a result, currently approved accommodating lenses typically can’t provide a full range of vision.
Multifocal patients often complain of seeing glare and halos, especially at night, in the first few months after surgery.
As a result, considerable time and money are being invested in the development of IOLs that reduce or eliminate the problems of current multifocals.
Typically, the eye’s “focusing” or ciliary muscle powers the movement or shape change.
Currently approved accommodating designs cause less loss of contrast sensitivity and are less likely than multifocal IOLs to produce glare and halos.
Multifocal IOLs incorporate discrete optical elements into the lens to offer both near and distance vision.